Question 1

What is SACITUZUMAB GOVITECAN used for?

Accepted Answer

SACITUZUMAB GOVITECAN (brand name TRODELVY) is a Other indicated for at least one of them for metastatic disease. ( 1.1, 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0.

Question 2

How does SACITUZUMAB GOVITECAN work?

Accepted Answer

SACITUZUMAB GOVITECAN works through the following mechanism: 12.1 Mechanism of Action Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. Sacituzumab govitecan-hziy decreased tumor growth in mouse xenograft models of triple-negative breast cancer..

Question 3

What are the most common side effects of SACITUZUMAB GOVITECAN?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for SACITUZUMAB GOVITECAN. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is SACITUZUMAB GOVITECAN the same as TRODELVY?

Accepted Answer

TRODELVY is a brand name for SACITUZUMAB GOVITECAN. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

SACITUZUMAB GOVITECAN

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations